The force of HER2 – a druggable target in NSCLC?
The past decade, systemic treatment of advanced non-small cell lung cancer (NSCLC) has undergone major changes. Several targeted therapies have been approved and recommended for use in subsets of patients who have specific genetic alterations [1]. One of these alterations involves the human epidermal growth factor 2 (HER2), a member of the ERBB family of tyrosine kinase receptors. Each receptor is composed of three segments: an extracellular ligand binding domain, an α-helical trans membrane segment and an intracellular tyrosine kinase domain.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: M. Jebbink, A.J. de Langen, M.C. Boelens, K. Monkhorst, E.F. Smit Tags: Anti-tumour Treatment Source Type: research